Hot Stocks to Start off the New Year: RIM, TEVA, WFR, BAC

The year 2010 was great for the stock market overall, but some stocks lagged the market, waiting for a better 2011. That that the new year is here, it is time for these well managed companies to shine.

Research in Motion (NASDAQ: RIMM) (TSE: RIM) has been knocked all over the place even with excellent quarterly reports and 40% revenue growth. With the launch of the long-awaited PlayBook, the stock is a candidate for some real profits. Currently, without the PlayBook, RIM earns more money than UPS (NYSE: UPS), has a much larger growth rate, and trades at less than half the market cap. To read the full report click here.

Teva Pharmaceutical (NASDAQ: TEVA) has investors worried about its monopolistic Copaxone drug. The new year should bring clarification on competitors' generic copies. At the end of 2010 Teva tried to get a concentrated version of its Copaxone approved, but it was quickly denied by the FDA. This could be good news if the FDA does not want to approve other similar drugs. To read the full report click here.

MEMC Electronic Materials (NYSE: WFR) is getting ready to earn some cash this year. Earlier in 2010 insiders purchased large amounts of shares. Most investors see the stock as a solar play - which it is - however it is essentially a play on oil. As the oil price moves up, companies will turn to clean energy such as solar. If oil once again reaches its 2007 highs, MEMC has large earnings power that could boost the stock to its 2007 highs as well. To read the full report click here.

Bank of America (NYSE: BAC) Of the large banks in the United States, Bank of America has lagged the rest. The company has been the center of negative attention, from Wiki Leaks to poor earnings. Last quarter the company earned over $3 billion, which was overshadowed by a $10 billion writedown of goodwill. The company trades just pennies over book value and is poised for a solid year of earnings. The bank may even be ready to start paying its once bountiful dividends once more. To read the full report click here.

Teva (NASDAQ: TEVA) up on bad news?

Teva Pharmaceutical (NASDAQ: TEVA) was up 2.9% in the last trading day amid news that a more concentrated version of its patented Copaxone drug would not be approved by the FDA. Copaxone is Teva's biggest product and fears of a generic version has caused the stock to stumble from the mid 60's. An extrapolation from the rejected version of its drug could mean that it would make it more difficult for other generic drugs to enter the market. This comes as great news for Teva and a small sigh of relief for investors who do not want to see a generic version of Copaxone.

To read the full report click here.

Is Teva Pharma Addicted to Drugs? (NASDAQ: TEVA)

Teva Pharmaceutical is expecting to earn $1.1 billion when it reports on Tuesday. The generic drug maker has been down on its luck in the past few months as some investors fear that it could lose patent protection on its top selling drug earlier than expected. Teva does specialize in generic drugs however, which some say is the way of the future.

"Marketing ability trumps patent protection when we're dealing with generic drugs," Said Andy "Raw" Kibbens, co-CEO of The Markets Are Open. "I believe TEVA is well positioned."

To read Kibbens' full report, click here.